Novo's NVO oral Wegovy (semaglutide) is showing real-world weight-loss benefits among adults with overweight or obesity who switched from injectable GLP-1 therapies. Data from the OCTANE study found that people moving from Eli Lilly's LLY Zepbound (tirzepatide) or injectable Wegovy to once-daily oral Wegovy lost an average of 4.1% of body weight after three months, highlighting the potential of an oral option for patients seeking an alternative to injections. Oral pills offer greater convenience than injectable therapies, making treatment easier to incorporate into daily routines and potentially supporting better treatment adherence.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.